Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for deve... Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. Mehr anzeigen
– Net product revenues for the third quarter 2024 totaled $429.8 million, a 39% increase over the same quarter of the prior year – ELEVIDYS net product revenue for the quarter totaled $181.0...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2024 (the “Grant Date”) that were previously approved by...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasdaq Global Market closes on...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2024 (the “Grant Date”) that were previously approved...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 29th Annual Congress of the World Muscle Society 2024 Congress (WMS...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 5.96 | 5.49106320251 | 108.54 | 114.5 | 102.155 | 1193079 | 107.11659951 | CS |
| 4 | -17.6 | -13.3232399697 | 132.1 | 133.36 | 102.155 | 1099836 | 117.5103726 | CS |
| 12 | -23.67 | -17.1310704205 | 138.17 | 138.71 | 102.155 | 896772 | 122.21658697 | CS |
| 26 | -14.43 | -11.1921197549 | 128.93 | 173.1 | 102.155 | 1392515 | 134.19466301 | CS |
| 52 | 30.08 | 35.6313669747 | 84.42 | 173.1 | 78.67 | 1224286 | 126.44092881 | CS |
| 156 | 33.36 | 41.1141237368 | 81.14 | 173.1 | 55.25 | 1175306 | 113.14189944 | CS |
| 260 | 10.3 | 9.88483685221 | 104.2 | 181.83 | 55.25 | 1131413 | 110.8018085 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
